Get the Stockscreener App
12.79
4.41%
0.54
Uniqure N V stock is traded at $12.79, with a volume of 3.14M.
It is up +4.41% in the last 24 hours and up +39.63% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
See More
Previous Close:
$12.25
Open:
$12.15
24h Volume:
3.14M
Relative Volume:
1.95
Market Cap:
$808.35M
Revenue:
$15.84M
Net Income/Loss:
$-308.48M
P/E Ratio:
-1.9738
EPS:
-6.48
Net Cash Flow:
$-153.08M
1W Performance:
-13.41%
1M Performance:
+39.63%
6M Performance:
+64.18%
1Y Performance:
+152.27%
1-Day Range:
$11.82
$13.77
1-Week Range:
$10.05
$16.20
52-Week Range:
$3.73
$19.18
Uniqure N V Stock (QURE) Company Profile
Name
Uniqure N V
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
12.79 | 808.35M | 15.84M | -308.48M | -153.08M | -6.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-01-25 | Resumed | Chardan Capital Markets | Buy |
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure N V Stock (QURE) Latest News
uniQure NV (QURE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline with Strategic ... - Yahoo
uniQure NV (QURE) Q1 2025 Earnings Call Highlights: Navigating R - GuruFocus
Uniqure NV earnings beat by $0.18, revenue fell short of estimates - Investing.com
Transcript : UniQure N.V., Q1 2025 Earnings Call, May 09, 2025 - marketscreener.com
QURE's Financial Position Strengthened by Recent Capital Raise | - GuruFocus
UniQure: Q1 Earnings Snapshot - MySA
uniQure (QURE) Reports Lower Q1 Revenue, Advances Huntington's T - GuruFocus
uniQure NV Reports Q1 2025 Earnings: EPS Loss of $0.82 Beats Est - GuruFocus
UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
uniQure NV Reports Q1 2025 Earnings: EPS Loss of $0.82 Beats Estimates, Revenue Falls Short at $1.6 Million - GuruFocus
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress - GlobeNewswire
UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
uniQure (QURE) Stock Decline Viewed as Overreaction by Analysts | QURE Stock News - GuruFocus
uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data - Seeking Alpha
(QURE) Proactive Strategies - news.stocktradersdaily.com
Uniqure NV expected to post a loss of $1.01 a shareEarnings Preview - TradingView
uniQure (QURE) Receives Steady "Buy" Rating from Chardan Capital - GuruFocus
uniQure to Announce First Quarter 2025 Financial Results - GlobeNewswire
Gene Therapy Leader uniQure Launches Quarterly Earnings Calls as AMT-130 Nears BLA Submission - Stock Titan
UniQure stock holds $70 target, buoyed by FDA breakthrough nod - Investing.com Australia
(QURE) Investment Analysis - news.stocktradersdaily.com
Gene therapy developers rise on comments from FDA's Makary - Seeking Alpha
uniQure (QURE) Moves 38.5% Higher: Will This Strength Last? - Yahoo Finance
uniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A Hold - Seeking Alpha
uniQure: Bullish On Near Term Catalysts After Breakthrough Therapy Designation For AMT-130 - Seeking Alpha
uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting - Seeking Alpha
uniQure jumps on FDA breakthrough tag for Huntington’s disease drug - MSN
AMT-130 gets FDA breakthrough therapy designation - European Biotechnology Magazine
FDA grants breakthrough status to uniQure’s Huntington’s therapy By Investing.com - Investing.com Canada
uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic By Stocktwits - Investing.com India
uniQure Stock Jumps On FDA’s Breakthrough Therapy Designation For Investigational Gene Therapy: Retail’s Optimistic - MSN
UniQure N.V. (QURE) Soars on FDA Breakthrough Therapy Designation for Huntington's Disease Treatment - RagingBull
uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday - Benzinga
Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday? - Benzinga
uniQure (QURE) Surges After FDA Grants Breakthrough Status to Gene Therapy - GuruFocus
uniQure stock jumps on FDA breakthrough tag (QURE:NASDAQ) - Seeking Alpha
uniQure (QURE) Revenue and EPS Fall Short of Expectations - GuruFocus
uniQure shares soar on FDA breakthrough therapy designation - Investing.com
uniQure shares soar on FDA breakthrough therapy designation By Investing.com - Investing.com Canada
FDA grants breakthrough status to uniQure’s Huntington’s therapy - Investing.com
uniQure (QURE) Secures Breakthrough Therapy Status for AMT-130 | - GuruFocus
UniQure's Huntington's Drug Gets FDA Breakthrough Therapy Designation - marketscreener.com
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease | QURE Stock News - GuruFocus
Uniqure Announces FDA Breakthrough Therapy Designation Granted To Amt-130 For The Treatment Of Huntington’S Disease - TradingView
uniQure N.V. Receives FDA Breakthrough Therapy Designation for AMT-130 in Huntington's Disease Treatment - Nasdaq
uniQure Announces FDA Breakthrough Therapy Designation - GlobeNewswire
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease - Yahoo
uniQure (NASDAQ:QURE) Shares Sold by Vanguard Group Inc. - Defense World
Hemophilia B Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | UniQure Biopharma B.V., CSL Behring, Pfizer/Spark Therapeutics, Genzyme Sanofi - Barchart.com
uniQure CEO secures amended employment agreement By Investing.com - Investing.com Canada
JPMorgan Chase & Co. Buys 58,246 Shares of uniQure (NASDAQ:QURE) - Defense World
Uniqure N V Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Uniqure N V Stock (QURE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Abi-Saab Walid | Chief Medical Officer |
Mar 04 '25 |
Sale |
10.29 |
1,350 |
13,891 |
151,903 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Mar 04 '25 |
Sale |
10.29 |
10,438 |
107,407 |
217,730 |
| Potts Jeannette | Chief Legal Officer |
Mar 04 '25 |
Sale |
10.29 |
7,076 |
72,812 |
119,743 |
| Kapusta Matthew C | CEO, Managing Director |
Feb 25 '25 |
Sale |
10.70 |
26,727 |
285,979 |
571,188 |
| Kapusta Matthew C | CEO, Managing Director |
Feb 27 '25 |
Sale |
11.32 |
6,717 |
76,036 |
580,795 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Feb 25 '25 |
Sale |
10.70 |
14,341 |
153,449 |
152,372 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Feb 27 '25 |
Sale |
11.32 |
2,916 |
33,009 |
155,168 |
| Kapusta Matthew C | CEO, Managing Director |
Dec 10 '24 |
Option Exercise |
14.71 |
100,000 |
1,471,000 |
697,915 |
| Kapusta Matthew C | CEO, Managing Director |
Dec 10 '24 |
Sale |
15.03 |
100,000 |
1,503,000 |
597,915 |
| Kapusta Matthew C | CEO, Managing Director |
Dec 09 '24 |
Sale |
7.63 |
3,418 |
26,079 |
597,915 |
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):